Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher H Goss

Showing results (101-110 of 229) with videos related to

Pageof 23
Sort By:
American Journal of Respiratory and Critical Care Medicine|September 5, 2009
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbationsPatrick A Flume, Peter J Mogayzel, Karen A Robinson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 2, 2024
Longitudinal changes in BMD in adults with cystic fibrosisReem Jad, Xiayi Ma, Sanja Stanojevic, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 26, 2015
Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United StatesKathleen J Ramos, Bradley S Quon, Kevin J Psoter, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 11, 2022
The lung allocation score and other available models lack predictive accuracy for post-lung transplant survivalJay M Brahmbhatt, Travis Hee Wai, Christopher H Goss, et al.
Contemporary Clinical Trials|November 25, 2017
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CFSonya L Heltshe, Natalie E West, Donald R VanDevanter, et al.
Chest|March 12, 2003
Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosisMoira L Aitken, Kelly E Greene, Mark R Tonelli, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 15, 2024
Impact of day-to-day variation in FEV1 on measures of change: A conceptual descriptionAmalia S Magaret, Ellen Graham, Lindsay J Caverly, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 2, 2023
Role of hyperglycemia in cystic fibrosis pulmonary exacerbationsLina Merjaneh, Aniket R Sidhaye, Phuong T Vu, et al.
The European Respiratory Journal|August 13, 2021
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II studyChristopher H Goss, Isabelle Fajac, Raksha Jain, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 19, 2023
Olfactory loss in people with cystic fibrosis: Community perceptions and impactJessa E Miller, Christine M Liu, Edith T Zemanick, et al.
Pageof 23

Showing results (101-110 of 229) with videos related to

Sort By:
Pageof 23
American Journal of Respiratory and Critical Care Medicine|September 5, 2009
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbationsPatrick A Flume, Peter J Mogayzel, Karen A Robinson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 2, 2024
Longitudinal changes in BMD in adults with cystic fibrosisReem Jad, Xiayi Ma, Sanja Stanojevic, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 26, 2015
Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United StatesKathleen J Ramos, Bradley S Quon, Kevin J Psoter, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 11, 2022
The lung allocation score and other available models lack predictive accuracy for post-lung transplant survivalJay M Brahmbhatt, Travis Hee Wai, Christopher H Goss, et al.
Contemporary Clinical Trials|November 25, 2017
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CFSonya L Heltshe, Natalie E West, Donald R VanDevanter, et al.
Chest|March 12, 2003
Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosisMoira L Aitken, Kelly E Greene, Mark R Tonelli, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 15, 2024
Impact of day-to-day variation in FEV1 on measures of change: A conceptual descriptionAmalia S Magaret, Ellen Graham, Lindsay J Caverly, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 2, 2023
Role of hyperglycemia in cystic fibrosis pulmonary exacerbationsLina Merjaneh, Aniket R Sidhaye, Phuong T Vu, et al.
The European Respiratory Journal|August 13, 2021
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II studyChristopher H Goss, Isabelle Fajac, Raksha Jain, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 19, 2023
Olfactory loss in people with cystic fibrosis: Community perceptions and impactJessa E Miller, Christine M Liu, Edith T Zemanick, et al.
Pageof 23